Background
Materials and patients
RA | 3DC | ||
---|---|---|---|
Number of patients
|
25
|
20
| |
Males
| 76% (19/25) | 65% (13/20) | |
Females
| 24% (6/25) | 35% (7/20) | |
Age [years] (median and range)
| 65.4 [37, 85] | 63.5 [46, 79] | |
Hystology
| Adenoca | Adenoca | |
Stage T
|
T2
| 0% (0/25) | 15% (3/20) |
T3
| 84% (21/25) | 75% (15/20) | |
T4
| 16% (4/25) | 10% (2/20) | |
Stage N
|
N0
| 48% (12/25) | 40% (8/20) |
N1
| 44% (11/25) | 35% (7/20) | |
N2
| 4% (1/25) | 10% (2/20) | |
Nx
| 4% (1/25) | 15% (3/20) | |
Stage M
|
M0
| 96% (24/25) | 95% (19/20) |
M1
| 4% (1/25) | 5% (1/20) | |
Grade G
|
G1
| 4% (1/25) | 10% 2/20) |
G2
| 84% (21/25) | 90% (18/20) | |
G3
| 12% (3/25) | 0% (0/20) | |
Location
|
Low
| 48% (12/25) | 15% (3/20) |
Medium
| 16% (4/25) | 45% (9/20) | |
High
| 36% (9/25) | 40% (8/20) | |
Chemotherapy
|
Capecitabin
| 92% (23/25) | 100% (20/20) |
No chemio
| 8% (2/25) | 0% (0/20) | |
Surgery
|
Pre-op
| 80% (20/25) | 90% (18/20) |
Post-op
| 16% (4/25) | 10% (2/20) | |
Non-op
| 4% (1/25) | 0% (0/20) | |
Radiation Dose Prescription
|
44 Gy/22 fractions
| 72% (18/25) | 80% (16/20) |
45 Gy/25 fractions
| 20% (5/25) | 20% (4/20) | |
40 Gy/20 fractions
| 8% (2/25) | 0% (0/20) | |
Radiation Boost
|
50.4 Gy
| 12% (3/25) | 25% (5/20) |
Dose Prescription
|
54.0 Gy
| 4% (1/25) | 0% (0/20) |
Results
RA | 3DC | |
---|---|---|
Number of arcs or fields
| 1 (25/25) | 3 (15/20), 4 (5/20) |
Arc length [°]
| 358 ± 0.0 | NA |
Beam energy
| 6 MV (25/25) | 6 MV (7/20) 15 MV (13/20) |
Beam on time [min]
| 1.24 ± 0.0 | 0.98 ± 0.2 |
Treatment Time [min]
| 2.05 ± 0.09 | 3.42 ± 0.25 |
MU
| 276 ± 32 | 293 ± 46 |
MU/Gy
| 141 ± 14 | 149 ± 21 |
MU/deg
| 0.8 ± 0.1 | NA |
Dose Rate [MU/min]
| 222 ± 25 | 300 |
Gantry speed [deg/sec]
| 4.8 ± 0.0 | NA |
Collimator angle [°]
| 24 ± 8 | 0 ± 0 |
Mean CP area [cm
2
]
| 156 ± 28 | NA |
Mean field area [cm
2
]
| 393 ± 75 | 249 ± 32 |
GAI [%]
| 98.33 ± 1.17 | NA |
RA | 3DC | P | |
---|---|---|---|
PTV
| |||
Volume [cm
3
]
| 1360 ± 250 | 1358 ± 218 | 0.98 |
Mean [Gy]
| 43.9 ± 1.3 | 44.0 ± 1.0 | 0.87 |
D
1%
[Gy]
| 46.1 ± 1.5 | 46.3 ± 1.4 | 0.65 |
D
5-95%
[Gy]
| 3.5 ± 0.8 | 4.0 ± 0.9 | 0.10 |
D
99%
[Gy]
| 41.0 ± 1.3 | 40.9 ± 0.9 | 0.75 |
V
95%
[%]
| 96.5 ± 2.7 | 95.3 ± 2.5 | 0.14 |
V
107%
[%]
| 0.2 ± 0.4 | 1.0 ± 2.1 | 0.07 |
CI
90%
| 1.2 ± 0.1 | 1.6 ± 0.1 | <0.01 |
CI
95%
| 1.1 ± 0.1 | 1.4 ± 0.1 | <0.01 |
Bladder
| |||
Volume [cm
3
]
| 190 ± 166 | 98.0 ± 36 | 0.02 |
Mean [Gy]
| 34.0 ± 4.2 | 32.7 ± 7.1 | 0.45 |
V
40 Gy
[cm
3
]
| 68.2 ± 38.4 | 46.5 ± 26.4 | 0.11 |
Bowels
| |||
Volume [cm
3
]
| 3417.7 ± 816.5 | 2609.0 ± 718.1 | 0.13 |
Mean [Gy]
| 5.9 ± 1.0 | 8.7 ± 5.2 | 0.27 |
D
1%
[Gy]
| 31.4 ± 4.0 | 37.8 ± 3.8 | 0.03 |
V
30 Gy
[%]
| 2.1 ± 2.6 | 8.7 ± 10.8 | 0.22 |
V
36 Gy
[%]
| 0.4 ± 0.8 | 4.8 ± 8.3 | 0.27 |
Femurs
| |||
Volume [cm
3
]
| 322.1 ± 101.2 | 315.4 ± 74.3 | 0.81 |
Mean [Gy]
| 8.7 ± 1.5 | 10.8 ± 1.7 | <0.01 |
D
1%
[Gy]
| 39.8 ± 1.9 | 43.9 ± 1.3 | <0.01 |
Healthy tissue
| |||
Volume [cm
3
]
| 24903 ± 6518 | 21629 ± 3838 | 0.05 |
Mean [Gy]
| 8.7 ± 1.5 | 10.8 ± 1.7 | <0.01 |
V
10 Gy
[%]
| 35.5 ± 6.6 | 35.8 ± 6.0 | 0.89 |
DoseInt
| 2.1 ± 0.5 | 2.3 ± 0.3 | <0.01 |
TNM | RA | 3DC | |
---|---|---|---|
Duration of RT [days] (for the 44/45 Gy course)
| 32 ± 4 [25-39] | 33 ± 7 [28-56] | |
Downstaging: (at surgery)
| T | 41% (7/17)* | 26% (5/19) |
N | 12% (2/17) | 21% (4/19) | |
Upstaging: (at surgery)
| T | 6% (1/17) | 11% (2/19) |
N | 18% (3/17) | 11% (2/19) | |
M | 6% (1/17) | 0% (0/19) |
RA | 3DC | ||
---|---|---|---|
Erithema
| G1/G2 | 28%(7/25) | 15% (3/20) |
G3/G4 | 0% (0/25) | 0%(0/20) | |
Diarrhoea
| G1/G2 | 40% (10/25) | 45% (9/20) |
G3/G4 | 8% (2/25) | 5% (1/20) | |
Disuria/incontinency
| G1/G2 | 0% (0/25) | 10%(2/20) |
G3/G4 | 0%(0/25) | 0% (0/20) |